Investigators Characterize Cancer Risk in Men With BRCA1/2 Pathogenic VariantsAugust 23rd 2020
Men who are carriers of a BRCA2 pathogenic variant were more likely to develop breast, prostate, and pancreatic cancers than patients harboring BRCA1, according to an analysis of male and female carriers of BRCA1/2 pathogenic variants.
Closing Gaps in Care: COVID-19 in Patients With Cancer Bring Health Inequities to the SurfaceAugust 22nd 2020
According to the CDC, patients at any age who have cancer are at an increased risk of severe illness due to coronavirus disease 2019 (COVID-19), and this may be aggravated by aspects such as race, ethnicity, and socioeconomic factors.
Observational Study of Radium-223 Reveals Safety and Pain Response in mCRPCAugust 22nd 2020
Short and longterm safety and a meaningful reduction in worst pain were reported in patients with metastatic castration-resistant prostate cancer, based on results from the REASSURE trial.
ISGIO Conference Explores Enhancing Fellows’ Experience, Ramifications of MSI-High PhenotypeAugust 15th 2020
As the new chair of the 17th Annual International Society of Gastrointestinal Oncology meeting, Tanios Bekaii-Saab, MD, said that this year’s virtual conference will place particular emphasis on fellows’ education and involvement.
Indications Continue to Expand for EGFR Targeted Therapies in Lung CancerAugust 14th 2020
Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.
Early Responses Observed With Lu-PSMA Administration May Provide Prognostic Outlook in mCRPCAugust 13th 2020
Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.